SG10201709967YA - Treatment regimens - Google Patents

Treatment regimens

Info

Publication number: SG10201709967YA
Authority: SG; Singapore
Prior art keywords: treatment regimens; regimens; treatment
Prior art date: 2012-08-06

Application number

SG10201709967YA

Inventor

Nicolas G Sitchon

Robert E Pyke

John F Kaufmann

Original Assignee

S1 Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-08-06

Filing date

2013-08-06

Publication date

2018-01-30

2013-08-06 Application filed by S1 Pharmaceuticals Inc filed Critical S1 Pharmaceuticals Inc

2018-01-30 Publication of SG10201709967YA publication Critical patent/SG10201709967YA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Reproductive Health (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)
Zoology (AREA)
Gynecology & Obstetrics (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Pregnancy & Childbirth (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

SG10201709967YA 2012-08-06 2013-08-06 Treatment regimens SG10201709967YA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201261679999P	2012-08-06	2012-08-06

Publications (1)

Publication Number	Publication Date
SG10201709967YA true SG10201709967YA (en)	2018-01-30

Family

ID=50068530

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
SG10201908587P SG10201908587PA (en)	2012-08-06	2013-08-06	Treatment regimens
SG11201500919PA SG11201500919PA (en)	2012-08-06	2013-08-06	Treatment regimens
SG10201709967YA SG10201709967YA (en)	2012-08-06	2013-08-06	Treatment regimens

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
SG10201908587P SG10201908587PA (en)	2012-08-06	2013-08-06	Treatment regimens
SG11201500919PA SG11201500919PA (en)	2012-08-06	2013-08-06	Treatment regimens

Country Status (15)

Country	Link
US (1)	US9517254B2 (en)
EP (1)	EP2879680A4 (en)
JP (2)	JP2015524474A (en)
KR (4)	KR20200128437A (en)
CN (2)	CN106924259A (en)
AU (2)	AU2013299725A1 (en)
BR (1)	BR112015002687A2 (en)
CA (1)	CA2881388A1 (en)
EA (1)	EA201590349A1 (en)
HK (2)	HK1214505A1 (en)
IL (1)	IL237150B (en)
MX (1)	MX2015001695A (en)
SG (3)	SG10201908587PA (en)
WO (1)	WO2014025814A1 (en)
ZA (1)	ZA201501562B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20170142797A (en) *	2016-06-17	2017-12-28	에스원 바이오파머, 인크.	Methods of Treating Women for Hypoactive Sexual Desire Disorder (HSDD) with Bupropion and Trazodone Combination Treatment
EP4486448A1 (en)	2022-03-04	2025-01-08	Reset Pharmaceuticals, Inc.	Co-crystals or salts comprising psilocin
WO2025042884A2 (en) *	2023-08-21	2025-02-27	Kuleon Llc	Serotonin receptor modulators for the treatment of addictions and overdoses
US11977085B1 (en)	2023-09-05	2024-05-07	Elan Ehrlich	Date rape drug detection device and method of using same

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4687771A (en) *	1985-11-01	1987-08-18	Bristol-Myers Company	Method for treatment of male impotence
DE4321965A1 (en) *	1993-07-01	1995-01-12	Cytech Biomedical Inc	Oxytocin-containing composition and the use thereof as remedy, in particular nasal spray for the treatment of sexual dysfunctions
US6337328B1 (en)	1999-03-01	2002-01-08	Sepracor, Inc.	Bupropion metabolites and methods of use
JP2002322085A (en) *	2001-04-26	2002-11-08	Kazuhito Tomizawa	Intelligent dysfunction therapeutic agent
UA78974C2 (en) *	2001-10-20	2007-05-10	Boehringer Ingelheim Pharma	Use of flibanserin for treating disorders of sexual desire
CN1711101A (en)	2002-10-03	2005-12-21	Pr药品有限公司	Treatment of autism and similar disorders
US20100143485A1 (en) *	2003-03-05	2010-06-10	Hudnut Paul S	Oxycontin controlled release formulations and methods of using same
WO2005102342A1 (en)	2004-04-22	2005-11-03	Boehringer Ingelheim International Gmbh	New pharmaceutical compositions for the treatment of sexual disorders ii
CN1946404A (en) *	2004-04-22	2007-04-11	贝林格尔·英格海姆国际有限公司	Pharmaceutical compositions for the treatment of sexual disorders II
US20060004076A1 (en)	2004-06-30	2006-01-05	Inflabloc Pharmaceuticals, Inc.	Co-administration of dehydroepiandrosterone (DHEA) congener with pharmaceutically active agents for treating inflammation
US20060122127A1 (en) *	2004-11-17	2006-06-08	Cypress Bioscience, Inc.	Methods for reducing the side effects associated with mirtzapine treatment
EP1858516A1 (en)	2005-03-04	2007-11-28	Boehringer Ingelheim International GmbH	Pharmaceutical compositions for the treatment and/or prevention of depression
US9023793B2 (en) *	2006-09-29	2015-05-05	Retrophin, Inc.	Intranasal carbetocin formulations and methods for the treatment of autism
MX2009004798A (en) *	2006-10-31	2009-08-12	Janssen Pharmaceutica Nv	Treatment of pervasive developmental disorders.
WO2008075162A2 (en) *	2006-12-15	2008-06-26	Pfizer Limited	Selective mu opioid receptor antagonists for the treatment of female sexual dysfunction
WO2009016488A2 (en) *	2007-08-02	2009-02-05	Compugen, Ltd.	Compositions comprising tetracyclic antidepressants for treatment of cancer and related methods
JP2012500801A (en) *	2008-08-21	2012-01-12	リヒターゲデオンニルバーノシャンミーケデーレスベニュタールシャシャーグ	CNS disease treatment
HRP20170089T1 (en) *	2009-01-20	2017-03-24	Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center	Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
AU2011252764B2 (en) *	2010-05-14	2012-12-13	Charlotte L. Keating	Neuropsychopharmacological treatment regimes for treating psychological disorders
EP2571360A4 (en) *	2010-05-19	2013-07-31	Univ North Carolina	METHODS AND FORMULATIONS FOR THE TREATMENT BY OXYTOCINE OF DISORDERS RELATED TO THE USE OF TOXIC SUBSTANCES, PSYCHIATRIC DISORDERS AND OTHER DISORDERS
WO2012016229A2 (en) *	2010-07-30	2012-02-02	The Regents Of The University Of California	Oxytocin treatment to improve memory and modify blood glucose
CN103635190B (en) *	2011-04-04	2016-09-07	S1生物药有限公司	Therapeutic scheme

2013
- 2013-08-06 CN CN201710010422.0A patent/CN106924259A/en active Pending
- 2013-08-06 CN CN201380052215.1A patent/CN104884060A/en active Pending
- 2013-08-06 KR KR1020207031031A patent/KR20200128437A/en not_active Ceased
- 2013-08-06 HK HK16102368.2A patent/HK1214505A1/en unknown
- 2013-08-06 EA EA201590349A patent/EA201590349A1/en unknown
- 2013-08-06 BR BR112015002687A patent/BR112015002687A2/en not_active IP Right Cessation
- 2013-08-06 KR KR1020257008033A patent/KR20250041078A/en active Pending
- 2013-08-06 SG SG10201908587P patent/SG10201908587PA/en unknown
- 2013-08-06 AU AU2013299725A patent/AU2013299725A1/en not_active Abandoned
- 2013-08-06 WO PCT/US2013/053843 patent/WO2014025814A1/en not_active Ceased
- 2013-08-06 KR KR1020237027646A patent/KR20230136142A/en not_active Ceased
- 2013-08-06 SG SG11201500919PA patent/SG11201500919PA/en unknown
- 2013-08-06 EP EP13827390.9A patent/EP2879680A4/en not_active Withdrawn
- 2013-08-06 SG SG10201709967YA patent/SG10201709967YA/en unknown
- 2013-08-06 KR KR1020157006024A patent/KR20150063039A/en not_active Ceased
- 2013-08-06 CA CA2881388A patent/CA2881388A1/en not_active Abandoned
- 2013-08-06 JP JP2015526649A patent/JP2015524474A/en not_active Ceased
- 2013-08-06 HK HK15112183.5A patent/HK1211239A1/en unknown
- 2013-08-06 MX MX2015001695A patent/MX2015001695A/en unknown
- 2013-08-06 US US14/420,112 patent/US9517254B2/en active Active
2015
- 2015-02-08 IL IL237150A patent/IL237150B/en active IP Right Grant
- 2015-03-06 ZA ZA2015/01562A patent/ZA201501562B/en unknown
2018
- 2018-05-30 JP JP2018103554A patent/JP2018150357A/en active Pending
- 2018-07-11 AU AU2018205121A patent/AU2018205121A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN106924259A (en)	2017-07-07
HK1211239A1 (en)	2016-05-20
AU2013299725A1 (en)	2015-03-26
WO2014025814A1 (en)	2014-02-13
KR20150063039A (en)	2015-06-08
JP2015524474A (en)	2015-08-24
KR20250041078A (en)	2025-03-25
EP2879680A4 (en)	2016-06-01
AU2018205121A1 (en)	2018-07-26
EA201590349A1 (en)	2015-07-30
IL237150A0 (en)	2015-04-30
MX2015001695A (en)	2015-09-28
IL237150B (en)	2018-07-31
EP2879680A1 (en)	2015-06-10
US9517254B2 (en)	2016-12-13
ZA201501562B (en)	2017-11-29
SG11201500919PA (en)	2015-04-29
SG10201908587PA (en)	2019-10-30
HK1214505A1 (en)	2016-07-29
JP2018150357A (en)	2018-09-27
BR112015002687A2 (en)	2019-12-17
US20150150946A1 (en)	2015-06-04
CN104884060A (en)	2015-09-02
CA2881388A1 (en)	2014-02-13
KR20230136142A (en)	2023-09-26
KR20200128437A (en)	2020-11-12

Publication	Publication Date	Title
IL254716B (en)	2020-02-27	Zinc-lysine complex
GB201212513D0 (en)	2012-08-29	Therapeutic agents
GB201217439D0 (en)	2012-11-14	Combination therapy
PT2838854T (en)	2018-11-02	Water treatment
GB201217704D0 (en)	2012-11-14	Therapeutic agents
GB201207305D0 (en)	2012-06-13	Therapy
ZA201501562B (en)	2017-11-29	Treatment regimens
ZA201409343B (en)	2016-08-31	Water treatment
ZA201307760B (en)	2015-01-28	Treatment regimens
EP2879707A4 (en)	2016-05-11	Combination therapy
PT2653448T (en)	2018-05-28	Water treatment
EP2904981A4 (en)	2016-05-25	Treatment tool
EP2804853A4 (en)	2015-09-23	Therapeutic uses
EP2704731A4 (en)	2015-02-11	Avian-based treatment
GB201102283D0 (en)	2011-03-23	Treatment
GB201211135D0 (en)	2012-08-08	Treatment
GB201208690D0 (en)	2012-06-27	Treatment
GB201212604D0 (en)	2012-08-29	New treatment
GB201211543D0 (en)	2012-08-15	Combination therapy
GB201221326D0 (en)	2013-01-09	Novel treatments
GB201215607D0 (en)	2012-10-17	Water treatment
GB201223021D0 (en)	2013-02-06	Therapeutic agents
GB201212512D0 (en)	2012-08-29	Therapeutic agents
GB201210233D0 (en)	2012-07-25	Therapeutic agents
GB201214030D0 (en)	2012-09-19	Concept six